---
title: "Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286635474.md"
description: "Serina Therapeutics, Inc. disclosed a PIPE deal involving director Gregory H. Bailey, which may dilute existing shareholders and increase governance risks. The deal, approved by a special committee, raises concerns about conflicts of interest and stockholder approval under NYSE rules. The average stock price target is $11.00, suggesting a 570.73% upside potential."
datetime: "2026-05-16T06:00:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286635474.md)
  - [en](https://longbridge.com/en/news/286635474.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286635474.md)
---

# Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks

Serina Therapeutics, Inc. (SER) has disclosed a new risk, in the Share Price & Shareholder Rights category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The March 2026 PIPE involving director Gregory H. Bailey, M.D., is expected to give him and other participating investors a potentially significant ownership stake in Serina Therapeutics, Inc., which could dilute existing stockholders and increase these investors’ influence over corporate decisions. Even though a special committee of independent directors approved the deal, the participation of an insider, combined with governance rights such as Dr. Bailey’s Co‑Chairman role and additional board designation rights, may heighten concerns about conflicts of interest, stockholder approval risk under NYSE American rules, and future volatility or downward pressure on the company’s stock price.

The average SER stock price target is $11.00, implying 570.73% upside potential.

To learn more about Serina Therapeutics, Inc.’s risk factors, click here.

### Related Stocks

- [SER.US](https://longbridge.com/en/quote/SER.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)